by Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Reguera R, Kreishman-Deitrick M, Buffet P, Croft SL. International Journal for Parasitology: Drugs and Drug Resistance 2019, doi: 10.1016/j.ijpddr.2019.06.003.
Summary: There have been significant advances in the treatment of visceral leishmaniasis and several novel compounds are currently in pre-clinical and clinical development. However, advances in drug research and development for cutaneous leishmaniasis have been more limited. The authors review the need for new treatments for cutaneous leishmaniasis and describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for cutaneous leishmaniasis.
This paper is a corrected proof.